MicroPort
心通医疗

MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

PROFIT FORECAST FOR THE YEAR OF 2024 — SIGNIFICANT REDUCTION IN NET LOSS

This announcement is made by MicroPort CardioFlow Medtech Corporation (the "**Company**", together with its subsidiaries, the "**Group**" or "**our**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "**Board**") of the Company is pleased to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary review of the unaudited management accounts of the Group for the year ended December 31, 2024 (the "**Reporting Period**") and an assessment of the latest information currently available to the Board, the Group is expected to record a net loss ranging approximately from RMB30 million to RMB60 million for the Reporting Period, representing a decrease of approximately between 87% to 94% as compared to that for the year ended December 31, 2023. Such decrease is mainly attributable to:

1) the orderly advancement of commercialization of our VitaFlow® and VitaFlow Liberty® transcatheter aortic heart valve implantation products and AnchorMan® left atrial appendage closure system and its access system in the PRC, with the implantation volume continuing to increase;

2) our VitaFlow Liberty® transcatheter aortic valve and retrievable delivery system obtained CE mark and achieved commercial implantations and sales in 17 overseas countries/regions during the Reporting Period, with overseas revenue more than doubling as compared to that for the year of 2023;

3) the Group's emphasis on the health of its financial statements and endeavors in focusing on business, continuously dedicated on the reduction of the product cost through optimizing manufacturing efficiency, diversifying material suppliers from multiple channels, and improving on productivity of key materials. In addition, the Group coordinated internal and external resources, leveraged intensive effect and firmly carried out cost management to improve operational efficiency and profitability and achieve healthy and sustainable business growth by evaluating the input-output of operating costs; and

4) 4C Medical Technologies, Inc. ("**4C Medical**"), an associate of the Group, closed its series D financing round in March 2025. Based on the new financing and the latest progress on its R&D projects, the Group reversed previously recognized impairment loss on the equity investment in 4C Medical; meanwhile, the Group also recognized fair value gains on the convertible instruments issued by 4C Medical.

As the Company is still in the process of finalising the results of the Group for the year ended December 31, 2024, the information contained in this announcement is only based on the Company's preliminary assessment of the unaudited consolidated management accounts and relevant revenue and expenses estimate made available to the Board as of the date of this announcement, which has not been audited or reviewed by the Company's auditors nor reviewed by the audit committee of the Company, and the above information may be subject to adjustments. Further details of the Group's financial information will be disclosed in the Group's results announcement for the year ended December 31, 2024, which is expected to be published in March 2025 according to the Listing Rules. As such, the above figures are provided for the Shareholders' and investors' reference only. Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for the year ended December 31, 2024.

Shareholders and potential investors are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, March 6, 2025

As of the date of this announcement, the executive Directors are Mr. Jeffrey R Lindstrom, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.